Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors.

Autor: London CA; Departments of Veterinary Biosciences and Clinical Sciences, The Ohio State University, Columbus, Ohio. cheryl.london@tufts.edu.; Cummings School of Veterinary Medicine, Tufts University, Grafton, Massachusetts., Acquaviva J; Synta Pharmaceuticals, Lexington, Massachusetts., Smith DL; Synta Pharmaceuticals, Lexington, Massachusetts., Sequeira M; Synta Pharmaceuticals, Lexington, Massachusetts., Ogawa LS; Synta Pharmaceuticals, Lexington, Massachusetts., Gardner HL; Sackler School of Graduate Biomedical Sciences, Tufts University, Boston, Massachusetts., Bernabe LF; Departments of Veterinary Biosciences and Clinical Sciences, The Ohio State University, Columbus, Ohio., Bear MD; Departments of Veterinary Biosciences and Clinical Sciences, The Ohio State University, Columbus, Ohio., Bechtel SA; Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, Missouri., Proia DA; Synta Pharmaceuticals, Lexington, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2018 Dec 15; Vol. 24 (24), pp. 6396-6407. Date of Electronic Publication: 2018 Aug 31.

A Novel HSP90 Inhibitor-Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer.

Autor: Gaponova AV; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.; Department of Biochemistry, Kazan Federal University, Kazan 420008, Russia., Nikonova AS; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Deneka A; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.; Department of Biochemistry, Kazan Federal University, Kazan 420008, Russia., Kopp MC; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.; Program in Molecular and Cell Biology and Genetics, Drexel University College of Medicine, Philadelphia, PA 19129, USA., Kudinov AE; University of New Mexico Comprehensive Cancer Center, University of New Mexico School of Medicine, Division of Hematology/Oncology, Department of Internal Medicine, Albuquerque, NM 87131., Skobeleva N; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Khazak V; Nexuspharma Inc., Langhorne, PA 19047., Ogawa LS; Synta Pharmaceuticals, Lexington, MA, 02421, USA., Cai KQ; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Duncan KE; Program in Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Duncan JS; Program in Cancer Biology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Egleston BL; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA., Proia DA; Synta Pharmaceuticals, Lexington, MA, 02421, USA., Boumber Y; University of New Mexico Comprehensive Cancer Center, University of New Mexico School of Medicine, Division of Hematology/Oncology, Department of Internal Medicine, Albuquerque, NM 87131., Golemis EA; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2016 Oct 15; Vol. 22 (20), pp. 5120-5129. Date of Electronic Publication: 2016 Jun 07.

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.

Autor: Landmann H; Göttingen Centre of Molecular Biosciences (GZMB), Institute of Molecular Oncology, Faculty of Medicine, University of Göttingen, 37077 Göttingen, Germany., Proia DA; Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA., He S; Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA., Ogawa LS; Synta Pharmaceuticals Corp, 45 Hartwell Avenue, Lexington, MA 02421, USA., Kramer F; Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany., Beißbarth T; Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany., Grade M; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany., Gaedcke J; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany., Ghadimi M; Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany., Moll U; 1] Göttingen Centre of Molecular Biosciences (GZMB), Institute of Molecular Oncology, Faculty of Medicine, University of Göttingen, 37077 Göttingen, Germany [2] Department of Pathology, School of Medicine, Stony Brook University, Stony Brook, NY 11794, USA., Dobbelstein M; Göttingen Centre of Molecular Biosciences (GZMB), Institute of Molecular Oncology, Faculty of Medicine, University of Göttingen, 37077 Göttingen, Germany.

Publikováno v: Cell death & disease [Cell Death Dis] 2014 Sep 11; Vol. 5, pp. e1411. Date of Electronic Publication: 2014 Sep 11.

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors.

Autor: Zhou D; Synta Pharmaceuticals Corp., 45 Hartwell Avenue, Lexington, MA 02421, USA. Electronic address: DZhou@syntapharma.com., Liu Y, Ye J, Ying W, Ogawa LS, Inoue T, Tatsuta N, Wada Y, Koya K, Huang Q, Bates RC, Sonderfan AJ

Publikováno v: Toxicology and applied pharmacology [Toxicol Appl Pharmacol] 2013 Dec 01; Vol. 273 (2), pp. 401-9. Date of Electronic Publication: 2013 Oct 01.